CL int-CYP3A4 and K m-CYP3A4 showed no effect on F a under the studied conditions. However, a significant effect on F G was observed throughout the range (CL int-CYP3A4 =0.01 to 2000 µL/min/mg) ( Figure 4 ). P app played a significant role in observing CYP3A4 saturation. P app values greater than 0.35·10 -6 cm/s at a dose of 100 mg were associated with saturation in some areas of K m-CYP3A4 and CL int-CYP3A4 parameter space studied (Figures 5 A, B and C ).
Introduction Introduction

Objectives Objectives
Method Method
Fig.2. Allocation of Simcyp ® library compounds according to BCS Class I-IV (F a =fraction absorbed into the enterocyte; Do=dose number).
Results Results
Active efflux by P-glycoprotein (P-gp) has been suggested to increase drug exposure to Cytochrome P450 3A (CYP3A) metabolising enzymes in the gastrointestinal tract, through cycling drug in and out of the enterocyte via absorption and active efflux, leading to a reduced fraction of drug escaping gut wall metabolism (F G ) (Benet & Cummins, 2001 ). However, when examining the transporter metabolism interplay using the Segmental Segregated Flow Model (SSFM) no evidence was found to support the above under linear kinetics (Pang 2003) , attributing any interplay to the nonlinear aspects of gut wall metabolism.
The ADAM model, within the Simcyp ® Simulator, is a comprehensive physiologically-based pharmacokinetic model, based on the Compartmental Absorption and Transit (ACAT) Model (Yu & Amidon, 1999) incorporating further features as compared to the SSFM (Pang 2003) , as described in detail by Jamei et al., (2009) .
Simulations were carried out using the ADAM model (see Figure 1) within the Simcyp Simulator (v 9.1). The star map shown in Figure 2 indicates the allocation of compounds within the Simcyp library to the four subdivisions of the Biopharmaceutics Classification System (BCS), relating to their estimated fraction absorbed into the enterocyte (F a estimated from measured or calculated human effective gut permeability), and dose number (Do), a measure of solubility (Amidon et al., 1995) .
To examine the impact of systemic variation in parameters relating to gut metabolism and transporter efflux interplay through studying the endpoints F a (fraction absorbed into the enterocyte) and F G, , utilising the ADAM model. Quinidine (QND) was chosen as an ideal starting point, varying the following parameters systematically:
• Passive permeability (P app ) (1 1-7 )
• CYP3A4 intrinsic clearance (CL int-CYP3A4 ) (2 1-7 )
• K m-CYP3A4 (3 1-5 )
• P-gp intrinsic clearance (4 1-7 )
• K m-Pgp (5 1-5 ) Resulting in a total of 8,575 simulations to be carried out (Figure 3) .
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Results suggest that P-gp efflux decreases enterocytic drug concentration for drugs given at a reasonably high dose, which possess adequate passive apparent permeability, by desaturating CYP3A4 in the gut resulting in a lower F G .
However, the P-gp / CYP3A4 interplay was observed in a very limited area of parameter space, matching very few therapeutic drugs expressing ( Figure 7 ):
• High degree of CYP3A metabolism • High affinity to P-gp efflux transporter • Low permeability
The systematic approach enabled us to recognise the combination of parameter values where the potential interplay between metabolising enzymes and efflux transporters is expected to be highest, using a realistic range of parameter values taken from an intensive literature search.
For a majority of Simcyp library compounds the effect of Pgp efflux on metabolism was negligible. The effect was limited to compounds such as saquinavir (Class III) and simvastatin (Class IV) (Figure 7 ).
